Amino Levulinic Acid 5 - ALA - Spot urine

The Amino Levulinic Acid 5 - ALA - Spot urine test measures 5-aminolevulinic acid, also called delta-aminolevulinic acid or ALA, in a single urine specimen. ALA is an early intermediate in the biochemical pathway used to produce haem. Haem is an essential component of haemoglobin and several enzymes involved in oxygen transport, energy production and normal cellular function.

ALA may accumulate when the haem-production pathway is disrupted. Increased urinary ALA can occur during certain acute hepatic porphyrias and after exposure to lead, which inhibits enzymes involved in haem synthesis. The test is therefore used as part of a broader evaluation rather than as a stand-alone diagnosis. Doctors commonly interpret it with urine porphobilinogen, porphyrins, blood lead levels and other clinical investigations.

Benefits of the Test

• Quantitatively measures ALA in a convenient spot urine sample.
• Supports investigation of suspected acute porphyria.
• May provide evidence of disruption to the haem-synthesis pathway.
• Assists in evaluating suspected lead exposure or toxicity.
• Can be interpreted with porphobilinogen and porphyrin testing.
• May support monitoring after a diagnosis or exposure has been established.

Why Doctors Recommend This Test

A physician may recommend urine ALA testing when a patient has episodes of severe unexplained abdominal pain, nausea, vomiting, constipation, weakness, rapid heartbeat, high blood pressure, confusion, anxiety, seizures, dark or reddish urine or other symptoms that raise concern about an acute porphyria. In acute hepatic porphyrias, symptoms may occur in attacks separated by periods of relative wellness.

Testing is most informative when the specimen is collected during or soon after an active symptomatic episode. Urine porphobilinogen is generally an important initial marker for most acute hepatic porphyrias and may be ordered with ALA. In ALA dehydratase-deficiency porphyria, ALA may be markedly elevated while porphobilinogen is not increased to the same degree.

The test may also be requested when lead exposure is possible. Lead can interfere with ALA dehydratase and other enzymes, resulting in increased ALA. Potential exposure can occur through certain occupations, contaminated dust or soil, old paint, batteries, metal recycling, traditional products or other environmental sources. A blood lead concentration is required for direct assessment of lead exposure; urinary ALA alone cannot confirm lead poisoning.

Preparation Before Test

Fasting is generally not required. Inform the doctor about all medicines, supplements, alcohol use, occupational exposure and recent symptoms. Some medicines and clinical factors can influence porphyria evaluation, but prescribed treatment should not be stopped without medical advice.

A clean-catch spot urine sample is collected in the container supplied or approved by the laboratory. The specimen should be protected from light immediately because porphyrin-related compounds can degrade with light exposure. The laboratory's refrigeration, freezing and transportation instructions should be followed carefully. Avoid contamination with stool, toilet water, tissue paper or cleaning products.

If possible, patients being assessed for an acute porphyria should collect the sample while symptoms are present and before disease-specific treatment begins, as advised by the treating doctor. The result may be reported relative to urine creatinine to account for variations in urine concentration.

Normal Reporting Time

Urine 5-ALA measurement is a specialized biochemical test and generally requires several working days. Reporting time varies according to specimen transportation, light protection, sample quality, analytical scheduling and whether repeat or confirmatory analysis is needed. Focus Diagnostics will provide the applicable turnaround estimate when the sample is submitted.

Who Should Take This Test?

• Patients with recurrent unexplained severe abdominal pain and neurological symptoms.
• People undergoing evaluation for a suspected acute hepatic porphyria.
• Individuals with possible occupational or environmental lead exposure.
• Patients with an abnormal urine porphobilinogen or porphyrin result.
• People with a family history of an acute porphyria.
• Patients requiring monitoring after a confirmed porphyria diagnosis or toxic exposure.
• Anyone specifically advised to undergo testing by a physician or metabolic specialist.

Detailed Information

Haem synthesis occurs through a sequence of enzyme-controlled reactions. ALA is produced early in this pathway and is normally converted to porphobilinogen by the enzyme ALA dehydratase. Enzyme deficiencies associated with porphyria or enzyme inhibition caused by lead can interrupt this process and increase ALA excretion.

An elevated ALA result does not identify the cause by itself. Doctors consider the degree of elevation, symptoms, urine porphobilinogen, total and fractionated porphyrins, blood lead concentration, liver and kidney function and medication history. Genetic testing may be recommended when biochemical findings support an inherited porphyria.

A normal ALA result collected when the patient has no symptoms may not fully exclude an intermittent acute porphyria. Repeat testing during a typical attack may be appropriate when clinical suspicion remains high. Dilute urine may also reduce the apparent concentration, which is why laboratories may calculate an ALA-to-creatinine ratio.

If lead exposure is suspected, evaluation may include blood lead, zinc protoporphyrin or free erythrocyte protoporphyrin, complete blood count, kidney function and environmental assessment. Treatment depends on the confirmed cause. Acute porphyria may require removal of triggers, carbohydrate support or intravenous haem therapy under specialist supervision. Lead exposure requires source removal and, in selected cases, medically supervised chelation.